Cargando…
(123)I-Meta-iodobenzylguanidine Sympathetic Imaging: Standardization and Application to Neurological Diseases
(123)I-meta-iodobenzylguanidine (MIBG) has become widely applied in Japan since its introduction to clinical cardiology and neurology practice in the 1990s. Neurological studies found decreased cardiac uptake of (123)I-MIBG in Lewy-body diseases including Parkinson's disease and dementia with L...
Autores principales: | Nakajima, Kenichi, Yamada, Masahito |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Chonnam National University Medical School
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5040763/ https://www.ncbi.nlm.nih.gov/pubmed/27689024 http://dx.doi.org/10.4068/cmj.2016.52.3.145 |
Ejemplares similares
-
Standardization of (123)I-meta-iodobenzylguanidine myocardial sympathetic activity imaging: phantom calibration and clinical applications
por: Nakajima, Kenichi, et al.
Publicado: (2017) -
Impact of Diabetes on Cardiac Sympathetic Innervation in Patients With Heart Failure: A (123)I meta-iodobenzylguanidine ((123)I MIBG) scintigraphic study
por: Paolillo, Stefania, et al.
Publicado: (2013) -
Validation of 2-year (123)I-meta-iodobenzylguanidine-based cardiac mortality risk model in chronic heart failure
por: Nakajima, Kenichi, et al.
Publicado: (2018) -
Diagnostic Accuracy of (123)I-Meta-Iodobenzylguanidine Myocardial Scintigraphy in Dementia with Lewy Bodies: A Multicenter Study
por: Yoshita, Mitsuhiro, et al.
Publicado: (2015) -
Cross calibration of (123)I-meta-iodobenzylguanidine heart-to-mediastinum ratio with D-SPECT planogram and Anger camera
por: Nakajima, Kenichi, et al.
Publicado: (2017)